{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310572","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.561357+00:00","generated_at":"2026-05-16T14:02:43.684729+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis","bullets":["KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.","Mean EASI reduction of 63% and mean peak pruritus NRS reduction of 40% across all patients; rapid onset by Day 8.","Type 2 biomarker reductions: TARC down 74% in patients with baseline ≥1,600 pg/mL; Eotaxin-3 reductions numerically exceeded dupilumab at 52 weeks.","First known demonstration of IL-31 reduction and FeNO reduction in AD patients via IL-4/13 pathway blockade.","Well-tolerated with no SAEs, no treatment-related AEs, no conjunctivitis; Phase 2b BROADEN2 ongoing (data mid-2027) and BREADTH asthma trial starts 1Q26."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310572","json":"https://secwatch.observer/filing/0001193125-25-310572.json","markdown":"https://secwatch.observer/filing/0001193125-25-310572.md","text":"https://secwatch.observer/filing/0001193125-25-310572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/0001193125-25-310572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/d69739d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:02:43.684729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}